Bactiguard appoints Patrick Bach new CFO
Bactiguard Holding AB (publ.) has appointed Patrick Bach as new CFO. Patrick comes most recently from Atos Medical where he had a variety of strategic leadership roles over a period of almost 10 years. He brings vast experience from the medtech industry and assumes the CFO position as of today. Patrick will be part of the Executive Management team at Bactiguard and report to the CEO.
Patrick Bach will, in addition to Group Finance, be responsible for Strategy and Digital at Bactiguard. Bactiguard’s current CFO, Carin Jakobson, assumes a role as Finance Director and leaves the Executive Management team. She will report to CFO Patrick Bach.
“As Bactiguard has entered the largest strategic shift in its history, to transform into a knowledge-driven partnership company, we are adding resources to match both the challenges and opportunities that lie ahead. In Patrick, we get a combination of finance and vast experience from the medtech industry as well as strategic, growth and transformation competence. Patrick shares our values and will be a great contributor to the entire firm,” says CEO Thomas von Koch.
“I am really looking forwad to joining Bactiguard, we are at a critical point where our infection prevention technology can make a huge impact to global healthcare issues, not the least antimicrobial resistance. The new license focused strategy is set to unleash Bactiguard’s full potential and I can’t wait to get to know the team and the business and chip in with full force to capture the exiciting opportunities that we have ahead of us," comments Patrick Bach, Bactiguard’s new CFO.
Patrick Bach was born in 1983 and holds a BSc in Economics and Business Administration and MSc in Finance and Strategic Management, both from Copenhagen Business School. Before Atos Medical, he worked with Coloplast Wound Care as Head of Strategy.
For further information, please contact:
Nina Nornholm, Head of Communication & IR +46 708 550 356
About Bactiguard
Bactiguard is a global medtech company that develops safe and biocompatible technology and solutions to prevent medical device related infections across five therapeutic areas – orthopedics, urology, intravascular/critical care, dental, and wound care.
Bactiguard’s unique technology is based on a thin noble metal coating that prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard’s infection prevention solutions make a positive impact by decreasing patient suffering, saving lives and unburden healthcare resources. They also fight against antimicrobial resistance, one of the most serious threats to global health and modern medicine.
Bactiguard operates through license partnerships with leading global medtech companies, such as BD and Zimmer Biomet, enabling them to bring medical devices with the company’s unique infection prevention technology to the market. Bactiguard also has a portfolio of wound management products and sutures.
Bactiguard is headquartered in Stockholm and listed on Nasdaq Stockholm.
Read more about Bactiguard: www.bactiguard.com
Follow Bactiguard on LinkedIn
